Survival, treatment patterns, and costs of HER2+ metastatic breast cancer patients in Ontario between 2005 to 2020.
Soo Jin SeungH SaherawalaD MoldaverS ShokarC AmmendoleaC Brezden-MasleyPublished in: Breast cancer research and treatment (2023)
The baseline characteristics and treatment patterns for patients who received HER2-TT in our study align with previously reported results. However, the mOS observed for 2L T-DM1 was shorter than that found in pivotal, clinical trial literature. As expected, anti-cancer systemic therapy costs were the main contributor to the over quarter-million dollar mean cost per patient on pert_tras in 1L.
Keyphrases
- clinical trial
- metastatic breast cancer
- end stage renal disease
- newly diagnosed
- systematic review
- chronic kidney disease
- stem cells
- case report
- prognostic factors
- type diabetes
- randomized controlled trial
- combination therapy
- insulin resistance
- bone marrow
- skeletal muscle
- metabolic syndrome
- adipose tissue
- weight loss
- glycemic control
- double blind
- free survival
- phase iii